FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078169517> ?p ?o ?g. }

• W2078169517 endingPage "9" @default.
• W2078169517 startingPage "7" @default.
• W2078169517 abstract "Chronic heart failure (C.H.F.) and cognitive impairment (C.I.) are both common problems in old age. They are both associated with significant mortality, impaired quality of life and disability. Common also to both conditions is the heavy economic burden they incur and the increasing proportion of Health and Social Service resources that they consume. The prevalence of C.H.F. is estimated to be 10% in those over the age of 75 years 1 rising to 15–20% over the age of 80. The prevalence of dementia is estimated at 8% in the over 65s 2. In addition many patients who have cognitive impairment do not fulfill the diagnostic criteria for dementia: cognitive impairment no dementia (C.I.N.D.) is twice as common as dementia, occurring in 17% of the population over the age of 65 years 3. Approximately 20% of all cases of dementia are predominantly vascular in aetiology 4. Many of the remainder have a vascular component. A vascular aetiology is particularly likely in the very elderly, over the age of 80 years. Given that this is the most rapidly expanding sector of the population, our ability to manage these conditions effectively in this age group is becoming increasingly important. While such common conditions as C.H.F. and C.I. may occur by chance within the same individuals there is some evidence to suggest that C.H.F. is independently associated with cognitive impairment. To date, only two studies have examined this area. The first was a small observational study of 57 consecutive heart failure admissions, mean age 77 years 5. The Mini Mental State Examination (M.M.S.E.), a screening test for cognitive impairment, was administered to all subjects. M.M.S.E. score of <24 (cut-off below which the probability of dementia is high) was found in 53% of participants. Older age and ejection fraction <30% were significant correlates of a lower M.M.S.E. score. The second study was a cross sectional community based study of 1075 patients over the age of 65 years 6. Again the M.M.S.E. was used and a score of <24 was found in 56.8% of patients with C.H.F. compared to only 20% of those without C.H.F. This association was independent of gender, age, educational level, geriatric depression score, diabetes, hypertension, alcohol consumption, smoking or presence of atrial fibrillation. There are as yet no published longitudinal studies following the natural history of cognitive change in C.H.F., although studies are ongoing. What then are the mechanisms by which C.H.F. might affect cognition? It is likely that impairment of cerebral circulation plays an important role. Low grade ischaemia of the deep white matter may be particularly important. Leukoaraiosis, a C.T. brain appearance of white matter low attenuation occurs in 70% of patients with vascular dementia 7, compared to <4% of healthy elderly people 8. It is associated with disability, gait disorders and cognitive impairment. Neuropathologically there is vascular remodelling with lipohyalinosis and narrowing of the penetrating arterioles. Subsequently there is hypoperfusion and ischaemia of white matter with resultant diffuse loss of myelin 9. Age, congestive heart failure and systolic blood pressure of <130 are all predictors of leukoaraiosis 10. In some series hypertension is also associated with leukoaraiosis. It is possible that the initial vascular remodelling is in response to raised mean arterial blood pressure. The ultrastructural changes do protect the brain against high perfusion pressure. However, the ability of the vessels to dilate at low pressure is also impaired. This then shifts both the upper and lower limits for cerebral blood flow auto-regulation. It is possible that with progressive heart failure as mean arterial pressure falls cerebral hypoperfusion of deep white matter results. Silent cerebral infarction is another potential way by which C.H.F. may impair cognition: it is frequently detected by brain C.T. and most commonly occurs in the basal ganglia and occipital lobes. The presence of congestive heart failure is an independent risk factor for silent cerebral infarction. Patients with CHF clearly often have multiple vascular risk factors and are, therefore, at risk of the full spectrum of stroke disorders: lacunar infarcts, cortical infarcts and multi-infarct state can all result in cognitive decline 11. Atrial fibrillation is frequently present in patients with CHF: the Rotterdam study has shown that atrial fibrillation is associated with both Alzheimer's disease and vascular dementia; and that this association cannot simply be accounted for by the occurrence of stroke 12. Case control studies of cognitive function in patients with AF have also shown consistently poorer performances in neuropsychological testing 13. However, in patients with CHF the association of cognitive impairment was independent of the presence of AF; while it may be a contributory factor it is not the sole explanation. CHF is associated with a hypercoagulable state: patients with CHF have elevated levels of thrombin/antithrombin complexes; beta-thromboglobulin; and D-dimers 14. Elevated fibrinogen levels have been reported in patients with lacunar infarcts and in leukoaraiosis 15; white matter ischaemia is also associated with increased fibrinogen and factor VIIc levels 16. Abnormalities of thrombosis and haemostasis may be important in the pathogenesis of ischaemic damage. In CHF there is abnormal vascular endothelial function: this is characterised by increased vasoconstriction and a reduced vasodilator response to exercise. Underlying this is up regulation of vascular ACE which inactivates bradykinin (a potent vasodilator which mediates its effect by release of nitric oxide, prostacyclin or endothelial derived hyper-polarisation factor) and produces angiotensin II 17. Tissue ACE is also important in the modulation of a number of neurotransmitters including encephalins, endorphins, neurotensin, substance P and kinins. It may be that changes in the levels of these substances may influence cognition 18. This also provides a potential target for therapy: ACE inhibitors increase the levels of the above neurotransmitters and through their effect on kinins raise concentrations of excitatory aminoacids, nitric oxide, prostaglandins, noradrenaline, and acetylcholine. This may be the mechanism for the improvement of memory and cognition suggested in studies of A.C.E. inhibitors in younger patients with hypertension. These trials are limited by the fact that A.C.E. inhibitors were usually compared with an alternative drug which may have had adverse effects on the above. There are few data on the effects of A.C.E. inhibitors on cognition in older patients. Cerebrovascular reactivity has recently been assessed in patients with CHF using transcranial Doppler to compare CO2 reactivity in heart failure patients with age-matched and normal controls 19. Reactivity was found to be impaired in all grades of heart failure compared to controls and in NYHA IV as compared to NYHA II and III patients. There was a significant relationship between cerebrovascular reactivity and left ventricular ejection fraction. It was postulated that patients with CHF compensate for the reduction in cardiac output by lowering cerebrovascular resistance through arteriolar dilatation. This however, renders them potentially unable to compensate for the additional effects of vasodilating or diuretic drugs. Impaired cerebrovascular reactivity may contribute to declining cognitive function. Can impaired cognition in heart failure patients be improved? The only data currently available are from highly selected groups undergoing cardiac transplantation. Two studies have yielded conflicting results: one suggested improvement in cognitive function following transplant 20 whereas the other was unable to demonstrate any change in cognition despite greatly improved physical health 21. Similarly there has been controversy over whether or not pacemaker implantation, which improves cerebral blood flow, improves cognition in elderly patients with bradycardia or heart block 22,23. Overall results have been disappointing. The theory that cognitive impairment in CHF might be prevented or attenuated is very attractive but remains untested. One current study, PEP-CHF, a randomised controlled trial of Perindopril in patients over 70 years with CHF and preserved systolic function does have a substudy of cognitive function 24. This should provide very useful information on the natural history of cognitive change in a population of older patients with CHF and on the effects of ACE inhibition in this group. Finally, hard endpoints such as mortality or days of hospitalisation are easy to record. Quality of life, disability and cognitive impairment are much more complex and time consuming to measure. Nonetheless, we would suggest that to our population of ageing, elderly heart failure patients who have multiple co-morbidities, these are the elements which matter. The whole field of cognitive impairment in patients with CHF is, we feel, worthy of further study and offers exciting opportunities for collaborative research between different specialities." @default.
• W2078169517 created "2016-06-24" @default.
• W2078169517 creator A5031245545 @default.
• W2078169517 creator A5077608684 @default.
• W2078169517 date "2002-01-01" @default.
• W2078169517 modified "2023-10-16" @default.
• W2078169517 title "Chronic heart failure and cognitive impairment: co-existence of conditions or true association?" @default.
• W2078169517 cites W1486819888 @default.
• W2078169517 cites W1972168387 @default.
• W2078169517 cites W2003410195 @default.
• W2078169517 cites W2005810979 @default.
• W2078169517 cites W2006551067 @default.
• W2078169517 cites W2007823877 @default.
• W2078169517 cites W2012022603 @default.
• W2078169517 cites W2014826564 @default.
• W2078169517 cites W2039393176 @default.
• W2078169517 cites W2052544532 @default.
• W2078169517 cites W2053331808 @default.
• W2078169517 cites W2072055122 @default.
• W2078169517 cites W2094396564 @default.
• W2078169517 cites W2101106890 @default.
• W2078169517 cites W2111936495 @default.
• W2078169517 cites W2138482871 @default.
• W2078169517 cites W2138704793 @default.
• W2078169517 cites W2145609805 @default.
• W2078169517 cites W2147599271 @default.
• W2078169517 cites W2159737123 @default.
• W2078169517 cites W2159898286 @default.
• W2078169517 cites W2172145526 @default.
• W2078169517 cites W2337054037 @default.
• W2078169517 cites W4384457762 @default.
• W2078169517 doi "https://doi.org/10.1016/s1388-9842(01)00182-9" @default.
• W2078169517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11812660" @default.
• W2078169517 hasPublicationYear "2002" @default.
• W2078169517 type Work @default.
• W2078169517 sameAs 2078169517 @default.
• W2078169517 citedByCount "34" @default.
• W2078169517 countsByYear W20781695172012 @default.
• W2078169517 countsByYear W20781695172013 @default.
• W2078169517 countsByYear W20781695172014 @default.
• W2078169517 countsByYear W20781695172015 @default.
• W2078169517 countsByYear W20781695172016 @default.
• W2078169517 countsByYear W20781695172018 @default.
• W2078169517 countsByYear W20781695172023 @default.
• W2078169517 crossrefType "journal-article" @default.
• W2078169517 hasAuthorship W2078169517A5031245545 @default.
• W2078169517 hasAuthorship W2078169517A5077608684 @default.
• W2078169517 hasBestOaLocation W20781695171 @default.
• W2078169517 hasConcept C118552586 @default.
• W2078169517 hasConcept C126322002 @default.
• W2078169517 hasConcept C142853389 @default.
• W2078169517 hasConcept C15744967 @default.
• W2078169517 hasConcept C164705383 @default.
• W2078169517 hasConcept C169900460 @default.
• W2078169517 hasConcept C2778198053 @default.
• W2078169517 hasConcept C2984915365 @default.
• W2078169517 hasConcept C542102704 @default.
• W2078169517 hasConcept C71924100 @default.
• W2078169517 hasConceptScore W2078169517C118552586 @default.
• W2078169517 hasConceptScore W2078169517C126322002 @default.
• W2078169517 hasConceptScore W2078169517C142853389 @default.
• W2078169517 hasConceptScore W2078169517C15744967 @default.
• W2078169517 hasConceptScore W2078169517C164705383 @default.
• W2078169517 hasConceptScore W2078169517C169900460 @default.
• W2078169517 hasConceptScore W2078169517C2778198053 @default.
• W2078169517 hasConceptScore W2078169517C2984915365 @default.
• W2078169517 hasConceptScore W2078169517C542102704 @default.
• W2078169517 hasConceptScore W2078169517C71924100 @default.
• W2078169517 hasIssue "1" @default.
• W2078169517 hasLocation W20781695171 @default.
• W2078169517 hasLocation W20781695172 @default.
• W2078169517 hasOpenAccess W2078169517 @default.
• W2078169517 hasPrimaryLocation W20781695171 @default.
• W2078169517 hasRelatedWork W1491055865 @default.
• W2078169517 hasRelatedWork W2012241433 @default.
• W2078169517 hasRelatedWork W2039995053 @default.
• W2078169517 hasRelatedWork W2051712573 @default.
• W2078169517 hasRelatedWork W2076843464 @default.
• W2078169517 hasRelatedWork W2077083067 @default.
• W2078169517 hasRelatedWork W2476173290 @default.
• W2078169517 hasRelatedWork W2965474825 @default.
• W2078169517 hasRelatedWork W4247718175 @default.
• W2078169517 hasRelatedWork W4315784592 @default.
• W2078169517 hasVolume "4" @default.
• W2078169517 isParatext "false" @default.
• W2078169517 isRetracted "false" @default.
• W2078169517 magId "2078169517" @default.
• W2078169517 workType "article" @default.